IL295042A - Human anti-tslp antibody formulations and methods for treating inflammatory disease - Google Patents
Human anti-tslp antibody formulations and methods for treating inflammatory diseaseInfo
- Publication number
- IL295042A IL295042A IL295042A IL29504222A IL295042A IL 295042 A IL295042 A IL 295042A IL 295042 A IL295042 A IL 295042A IL 29504222 A IL29504222 A IL 29504222A IL 295042 A IL295042 A IL 295042A
- Authority
- IL
- Israel
- Prior art keywords
- aqueous composition
- calcium
- arginine
- glutamate
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976007P | 2020-02-13 | 2020-02-13 | |
| US202163148105P | 2021-02-10 | 2021-02-10 | |
| PCT/US2021/017880 WO2021163504A1 (en) | 2020-02-13 | 2021-02-12 | Formulations of human anti-tslp antibodies and methods of treating inflammatory disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL295042A true IL295042A (en) | 2022-09-01 |
Family
ID=74858823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295042A IL295042A (en) | 2020-02-13 | 2021-02-12 | Human anti-tslp antibody formulations and methods for treating inflammatory disease |
Country Status (18)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI917325B (zh) | 2019-06-04 | 2026-03-11 | 大陸商江蘇恆瑞醫藥股份有限公司 | 能結合胸腺基質淋巴細胞生成素的抗體及其應用 |
| MX2023006596A (es) * | 2020-12-03 | 2023-06-19 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composicion farmaceutica de anticuerpo anti-tslp y uso de la misma. |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| TW202529809A (zh) * | 2023-10-17 | 2025-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種抗tslp抗體的醫藥組成物及其用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| EP3594356A1 (en) | 2009-11-04 | 2020-01-15 | Merck Sharp & Dohme Corp. | Engineered anti-tslp antibody |
| AR080428A1 (es) * | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| SMT202000095T1 (it) * | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| ES2964713T3 (es) * | 2014-10-23 | 2024-04-09 | Amgen Inc | Reducción de la viscosidad de formulaciones farmacéuticas |
| CN107428828A (zh) | 2015-03-11 | 2017-12-01 | 葛兰素史密斯克莱知识产权发展有限公司 | Tslp结合蛋白 |
| EA038332B1 (ru) | 2015-09-09 | 2021-08-10 | Новартис Аг | Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул |
| US10994011B2 (en) * | 2015-12-18 | 2021-05-04 | Astellas Pharma Inc. | Pharmaceutical composition comprising anti-human TSLP receptor antibody |
| EP3609917A1 (en) * | 2017-04-12 | 2020-02-19 | Amgen Inc. | Treatment of asthma with anti-tslp antibody |
| MA48461A (fr) * | 2017-04-28 | 2020-03-04 | Amgen Inc | Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation |
| CA3066399A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Torque driven drug delivery device |
| KR20200034748A (ko) * | 2017-07-27 | 2020-03-31 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Sost 항체 약학적 조성물 및 그의 용도 |
| IL319987A (en) | 2017-11-10 | 2025-06-01 | Amgen Inc | Plungers for drug delivery devices |
| WO2019178151A1 (en) | 2018-03-13 | 2019-09-19 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| JP7719714B2 (ja) | 2018-10-15 | 2025-08-06 | アムジエン・インコーポレーテツド | ダンピング機構を有する薬物送達装置 |
| MA53913A (fr) | 2018-10-15 | 2022-01-19 | Amgen Inc | Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament |
| AU2020397170A1 (en) * | 2019-12-05 | 2022-07-21 | Sanofi-Aventis U.S. Llc | Formulations of anti-CD38 antibodies for subcutaneous administration |
-
2021
- 2021-02-12 CR CR20220457A patent/CR20220457A/es unknown
- 2021-02-12 CN CN202180017163.9A patent/CN115279404A/zh active Pending
- 2021-02-12 CA CA3166964A patent/CA3166964A1/en active Pending
- 2021-02-12 AU AU2021219839A patent/AU2021219839A1/en active Pending
- 2021-02-12 KR KR1020227030979A patent/KR20220140772A/ko active Pending
- 2021-02-12 PE PE2022001741A patent/PE20230112A1/es unknown
- 2021-02-12 WO PCT/US2021/017880 patent/WO2021163504A1/en not_active Ceased
- 2021-02-12 EP EP21710162.5A patent/EP4103235A1/en active Pending
- 2021-02-12 UY UY0001039083A patent/UY39083A/es unknown
- 2021-02-12 US US17/760,427 patent/US20230078678A1/en active Pending
- 2021-02-12 JP JP2022548653A patent/JP2023513312A/ja active Pending
- 2021-02-12 BR BR112022016010A patent/BR112022016010A2/pt unknown
- 2021-02-12 PH PH1/2022/552050A patent/PH12022552050A1/en unknown
- 2021-02-12 IL IL295042A patent/IL295042A/en unknown
- 2021-02-12 MX MX2022010012A patent/MX2022010012A/es unknown
-
2022
- 2022-08-11 JO JOP/2022/0183A patent/JOP20220183A1/ar unknown
- 2022-08-12 CL CL2022002193A patent/CL2022002193A1/es unknown
- 2022-09-09 CO CONC2022/0012868A patent/CO2022012868A2/es unknown
-
2026
- 2026-02-02 JP JP2026015698A patent/JP2026074118A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220457A (es) | 2023-01-09 |
| JP2026074118A (ja) | 2026-05-01 |
| WO2021163504A1 (en) | 2021-08-19 |
| AU2021219839A1 (en) | 2022-08-25 |
| EP4103235A1 (en) | 2022-12-21 |
| CN115279404A (zh) | 2022-11-01 |
| PH12022552050A1 (en) | 2024-02-12 |
| UY39083A (es) | 2021-08-31 |
| JOP20220183A1 (ar) | 2023-01-30 |
| CO2022012868A2 (es) | 2022-12-09 |
| US20230078678A1 (en) | 2023-03-16 |
| MX2022010012A (es) | 2022-09-07 |
| CA3166964A1 (en) | 2021-08-19 |
| KR20220140772A (ko) | 2022-10-18 |
| PE20230112A1 (es) | 2023-01-27 |
| BR112022016010A2 (pt) | 2022-12-20 |
| CL2022002193A1 (es) | 2023-03-24 |
| JP2023513312A (ja) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295511A (en) | Formulations of human anti-tslp antibodies and methods of using them | |
| JP5931442B2 (ja) | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 | |
| US20230078678A1 (en) | Formulations of human anti-tslp antibodies and methods of treating atopic dermatitis | |
| US12509509B2 (en) | Solution formulations of engineered anti-IL-23p19 antibodies | |
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP2020500195A (ja) | アフリベルセプト製剤及びその使用 | |
| US20210379183A1 (en) | METHODS OF TREATING IgA NEPHROPATHY WITH AN APRIL BINDING ANTIBODY | |
| US12534525B2 (en) | Aqueous pharmaceutical composition of an anti-IL17A antibody and use thereof | |
| IL322225A (en) | Treatment of chronic rhinosinusitis using anti-TSLP antibody | |
| JP6592600B2 (ja) | 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用 | |
| EA046767B1 (ru) | Составы на основе антител к tslp человека и способы лечения воспалительного заболевания | |
| TW202140072A (zh) | 人抗tslp 抗體的配製物及治療炎性疾病之方法 | |
| RU2801204C2 (ru) | Способ лечения атопического дерматита посредством введения ингибитора ил-4r | |
| IL301548A (en) | Compounds and methods for treating pain | |
| IL303350A (en) | Preparations containing an antibody against HER2/NEU and their use | |
| TW201828984A (zh) | 使用介白素-17(il-17)拮抗劑治療痤瘡的方法 | |
| EP4647084A1 (en) | Method for treating asthma by using tslp antibody | |
| EA053285B1 (ru) | Составы на основе антител к tslp человека и способы их применения |